BIIB:NASDAQ
Biogen Inc
$222.89
arrow_downward
-0.31%(-0.70) 1D
$222.51
arrow_downward
-0.17% (-0.38)bedtimeAfter hours
Closed: Oct 6, 4:00:01 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BIIB...
Open
$224.53
High
$225.97
Low
$218.00
Mkt. cap
32.39B
Avg. vol.
952.02K
Volume
1.01M
P/E ratio
39.47
52-wk high
$230.49
52-wk low
$138.00
EPS
$5.65
Beta
0.09
Shares outstanding
147.75M
No. of employees
8K
Open
$224.53
High
$225.97
Low
$218.00
Mkt. cap
32.39B
Avg. vol.
952.02K
Volume
1.01M
P/E ratio
39.47
52-wk high
$230.49
52-wk low
$138.00
EPS
$5.65
Beta
0.09
Shares outstanding
147.75M
No. of employees
8K
News stories
From web sources and news partners
AD HOC NEWS
·
4 hours ago
Biogen stock heads toward October 28 results after 1.69 percent gain
Zacks
·
10 hours ago
Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report?
Proactive financial news
·
14 hours ago
Biogen expected to slightly beat third-quarter earnings as lupus trial data loom, Jefferies says
Kalkine Media
·
16 hours ago
Why Is Biogen (NASDAQ:BIIB) Moving Back Into Focus?
Profile
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs.
The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000. Wikipedia
About Biogen Inc
CEOChris Viehbacher
Employees7.5K
Founded1978
HeadquartersCambridge, Massachusetts, United States
SectorBiotechnology
Websitebiogen.com